Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385900444> ?p ?o ?g. }
- W4385900444 endingPage "1579" @default.
- W4385900444 startingPage "1563" @default.
- W4385900444 abstract "ABSTRACT The discovery and development of erythropoiesis-stimulating agents was a journey lasting more than a century, leading to the cloning and approval of recombinant human erythropoietin (rHuEpo). This was an impressive clinical advance, providing the possibility of correcting the symptoms associated with anaemia in chronic kidney disease. Associated iron use was needed to produce new haemoglobin-containing blood red cells. Partial anaemia correction became the standard of care since trials aiming for near-normal haemoglobin levels showed a higher risk of adverse cardiovascular events. Hoping to reduce the cardiovascular risks, a new category of drugs was developed and tested. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are small molecules than can be formulated into orally active pills. They simulate reduced tissue oxygen pressure, thus stimulating the production of endogenous erythropoietin (Epo) by the kidneys and liver. Clinical trials with these compounds demonstrated that HIF-PHIs are at least as effective as rHuEpo in treating or correcting anaemia in non-dialysis and dialysis patients. Trials with HIF-PHIs did not demonstrate superiority in safety outcomes and in some trials, outcomes were worse. There was also a focus on oral delivery, a possible beneficial iron-sparing effect and the ability to overcome Epo resistance in inflamed patients. A negative effect is possible iron depletion, which may explain adverse outcomes." @default.
- W4385900444 created "2023-08-18" @default.
- W4385900444 creator A5004472342 @default.
- W4385900444 creator A5071768099 @default.
- W4385900444 creator A5043198216 @default.
- W4385900444 date "2023-08-17" @default.
- W4385900444 modified "2023-10-17" @default.
- W4385900444 title "The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors" @default.
- W4385900444 cites W126815908 @default.
- W4385900444 cites W1541049769 @default.
- W4385900444 cites W1661558881 @default.
- W4385900444 cites W185516115 @default.
- W4385900444 cites W1912376315 @default.
- W4385900444 cites W1917991231 @default.
- W4385900444 cites W1972590090 @default.
- W4385900444 cites W1984305640 @default.
- W4385900444 cites W1986604740 @default.
- W4385900444 cites W1987536739 @default.
- W4385900444 cites W1998943227 @default.
- W4385900444 cites W2000457934 @default.
- W4385900444 cites W2004714439 @default.
- W4385900444 cites W2005973637 @default.
- W4385900444 cites W2010967452 @default.
- W4385900444 cites W2011032170 @default.
- W4385900444 cites W2019289959 @default.
- W4385900444 cites W2021529165 @default.
- W4385900444 cites W2023900607 @default.
- W4385900444 cites W2029774820 @default.
- W4385900444 cites W2033803279 @default.
- W4385900444 cites W2040029744 @default.
- W4385900444 cites W2044549731 @default.
- W4385900444 cites W2046224330 @default.
- W4385900444 cites W2047816152 @default.
- W4385900444 cites W2048837770 @default.
- W4385900444 cites W2055802293 @default.
- W4385900444 cites W2059154055 @default.
- W4385900444 cites W2076801187 @default.
- W4385900444 cites W2078061002 @default.
- W4385900444 cites W2078629931 @default.
- W4385900444 cites W2085609942 @default.
- W4385900444 cites W2088293785 @default.
- W4385900444 cites W2093098384 @default.
- W4385900444 cites W2101022307 @default.
- W4385900444 cites W2106855201 @default.
- W4385900444 cites W2107096899 @default.
- W4385900444 cites W2107327256 @default.
- W4385900444 cites W2120601666 @default.
- W4385900444 cites W2120939456 @default.
- W4385900444 cites W2124116160 @default.
- W4385900444 cites W2128490296 @default.
- W4385900444 cites W2134487085 @default.
- W4385900444 cites W2135454486 @default.
- W4385900444 cites W2136542175 @default.
- W4385900444 cites W2139318112 @default.
- W4385900444 cites W2141783200 @default.
- W4385900444 cites W2149688292 @default.
- W4385900444 cites W2151861887 @default.
- W4385900444 cites W2165758929 @default.
- W4385900444 cites W2178101235 @default.
- W4385900444 cites W2218631951 @default.
- W4385900444 cites W2242382501 @default.
- W4385900444 cites W2283665688 @default.
- W4385900444 cites W2315613377 @default.
- W4385900444 cites W2321377008 @default.
- W4385900444 cites W2550969996 @default.
- W4385900444 cites W2576202064 @default.
- W4385900444 cites W2580449060 @default.
- W4385900444 cites W2584947097 @default.
- W4385900444 cites W2767839794 @default.
- W4385900444 cites W2773387077 @default.
- W4385900444 cites W2898498137 @default.
- W4385900444 cites W2905055569 @default.
- W4385900444 cites W2952134395 @default.
- W4385900444 cites W2966965512 @default.
- W4385900444 cites W2967575218 @default.
- W4385900444 cites W3021994385 @default.
- W4385900444 cites W3030888994 @default.
- W4385900444 cites W3108166106 @default.
- W4385900444 cites W3112489277 @default.
- W4385900444 cites W3120425057 @default.
- W4385900444 cites W3128080784 @default.
- W4385900444 cites W3130258858 @default.
- W4385900444 cites W3130391515 @default.
- W4385900444 cites W3132161708 @default.
- W4385900444 cites W3155430778 @default.
- W4385900444 cites W3157159493 @default.
- W4385900444 cites W3159725307 @default.
- W4385900444 cites W3164802324 @default.
- W4385900444 cites W3175251345 @default.
- W4385900444 cites W3177691451 @default.
- W4385900444 cites W3188004162 @default.
- W4385900444 cites W3189027700 @default.
- W4385900444 cites W3199302640 @default.
- W4385900444 cites W39811204 @default.
- W4385900444 cites W4200289499 @default.
- W4385900444 cites W4205949640 @default.
- W4385900444 cites W4224247054 @default.
- W4385900444 cites W4225290475 @default.